Great Point Partners LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Great Point Partners LLC reported 31 stock positions worth $184.0 million. Its top holding was Cytokinetics (CYTK) at 8.1% of the portfolio, followed by Kalvista Pharmaceuticals (KALV, 6.4%) and Evolus (EOLS, 6.2%). Compared with Q4 2024, it opened 9 new positions, sold out of 4, added to 6 and reduced 8. The biggest buy was a new position in Akebia Therapeutics (AKBA) and the biggest sale Pliant Therapeutics (PLRX, shares −19%).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $184.0M (Q1 2025)
- SEC Filing
- 0001172661-25-002331 ↗ filed May 15, 2025
Holdings Value
Holdings 31 stocks · $184.0M
| CYTK Cytokinetics Inc. | 8.08% | 370,000 | $14.9M | Add +2.8% |
| KALV Kalvista Pharmaceuticals Inc. | 6.36% | 1,014,367 | $11.7M | Reduce -43.2% |
| EOLS Evolus Inc. | 6.18% | 944,743 | $11.4M | Add +5.5% |
| ABVX Abivax SA-ADR | 5.57% | 1,638,111 | $10.2M | Reduce -0.6% |
| VRDN Viridian Therapeutics Inc. | 5.50% | 750,000 | $10.1M | No change |
| MRUS Merus NV | 5.43% | 237,156 | $10.0M | Add +50.0% |
| AKBA Akebia Therapeutics Inc. | 5.19% | 4,973,840 | $9.5M | New |
| XENE Xenon Pharmaceuticals Inc. | 4.47% | 245,272 | $8.2M | No change |
| ASND Ascendis Pharma A/S | 4.24% | 50,000 | $7.8M | New |
| DVAX Dynavax Technologies Corp. | 4.20% | 595,879 | $7.7M | Reduce -30.7% |
| IONS Ionis Pharmaceuticals Inc. | 4.10% | 250,000 | $7.5M | Reduce -50.5% |
| AMLX Amylyx Pharmaceuticals Inc. | 3.49% | 1,811,996 | $6.4M | New |
| IMVT Immunovant Inc. | 3.48% | 375,000 | $6.4M | New |
| UNICYCIVE THERAPEUTICS INC | 3.43% | 10,980,000 | $6.3M | No change |
| NGNE Neurogene Inc. | 3.00% | 470,964 | $5.5M | Add +6.4% |
| DNTH Dianthus Therapeutics Inc. | 2.71% | 275,000 | $5.0M | No change |
| LEGN Legend Biotech Corp.-ADR | 2.55% | 138,240 | $4.7M | New |
| PCVX Vaxcyte Inc. | 2.37% | 115,517 | $4.4M | New |
| AUTL Autolus Therapeutics PLC | 2.30% | 2,728,910 | $4.2M | Reduce -9.3% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 2.30% | 373,833 | $4.2M | Reduce -25.2% |
| ZURA Zura Bio Ltd. | 2.22% | 3,170,194 | $4.1M | No change |
| BEAM Beam Therapeutics Inc. | 1.86% | 175,562 | $3.4M | New |
| ACLX Arcellx Inc. | 1.60% | 45,000 | $3.0M | New |
| MREO Mereo Biopharma Group PL-ADR | 1.56% | 1,275,000 | $2.9M | Add +10.9% |
| CNTX Context Therapeutics Inc. | 1.56% | 4,683,711 | $2.9M | No change |
| RZLT Rezolute Inc. | 1.31% | 833,042 | $2.4M | Add +34.0% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.17% | 149,702 | $2.2M | New |
| VYGR Voyager Therapeutics Inc. | 1.15% | 626,275 | $2.1M | Reduce -24.3% |
| PMN Promis Neurosciences Inc. | 1.00% | 2,645,128 | $1.8M | No change |
| UPB Upstream Bio Inc. | 1.00% | 300,000 | $1.8M | No change |
| PLRX Pliant Therapeutics Inc. | 0.62% | 850,000 | $1.1M | Reduce -19.4% |
Options reported separately and not counted above: SMMT puts ($4.8M).
Portfolio Sells Q4 2024 → Q1 2025
| PLRX Pliant Therapeutics Inc. | Reduce -19.4% | 0.62% | −5.92 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -50.5% | 4.10% | −4.22 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −3.25 |
| ORKA Oruka Therapeutics Inc. | Sold out | 0.00% | −2.09 |
| OPTINOSE INC | Sold out | 0.00% | −1.17 |
| VYGR Voyager Therapeutics Inc. | Reduce -24.3% | 1.15% | −1.06 |
| AUTL Autolus Therapeutics PLC | Reduce -9.3% | 2.30% | −1.03 |
| DVAX Dynavax Technologies Corp. | Reduce -30.7% | 4.20% | −0.97 |
| URGN Urogen Pharma Ltd. | Sold out | 0.00% | −0.94 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -43.2% | 6.36% | −0.77 |
| BBOT Bridgebio Oncology Therapeut | Reduce -25.2% | 2.30% | −0.18 |
| ABVX Abivax SA-ADR | Reduce -0.6% | 5.57% | −0.12 |
Portfolio Buys Q4 2024 → Q1 2025
| AKBA Akebia Therapeutics Inc. | New | 5.19% | +5.19 |
| ASND Ascendis Pharma A/S | New | 4.24% | +4.24 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 3.49% | +3.49 |
| IMVT Immunovant Inc. | New | 3.48% | +3.48 |
| LEGN Legend Biotech Corp.-ADR | New | 2.55% | +2.55 |
| PCVX Vaxcyte Inc. | New | 2.37% | +2.37 |
| MRUS Merus NV | Add +50.0% | 5.43% | +2.29 |
| BEAM Beam Therapeutics Inc. | New | 1.86% | +1.86 |
| ACLX Arcellx Inc. | New | 1.60% | +1.60 |
| EOLS Evolus Inc. | Add +5.5% | 6.18% | +1.52 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 1.17% | +1.17 |
| CYTK Cytokinetics Inc. | Add +2.8% | 8.08% | +0.10 |
| RZLT Rezolute Inc. | Add +34.0% | 1.31% | −0.12 |
| MREO Mereo Biopharma Group PL-ADR | Add +10.9% | 1.56% | −0.34 |
| NGNE Neurogene Inc. | Add +6.4% | 3.00% | −1.77 |
Options Activity Q4 2024 → Q1 2025
| SMMT Summit Therapeutics Inc. | put | New | 250,000 | $4.8M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |